Investor Overview ‹ Arena Pharmaceuticals, Inc.

Investor Overview

Arena Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing novel drugs for weight management, cardiovascular disease, inflammation and other disorders.

In June 2012, the US Food and Drug Administration (FDA) approved our internally discovered and developed drug, BELVIQ^® (lorcaserin HCl). BELVIQ will be available to patients in the United States by prescription following its June 7, 2013, Schedule IV effective date. Following are links to certain additional information:

We have granted exclusive marketing and distribution rights to Eisai Inc. for most of North and South America, and to Ildong Pharmaceutical Co., Ltd., for South Korea. We plan to enter into additional collaborations to commercialize BELVIQ outside of these territories.

BELVIQ is approved by the US Food and Drug Administration and will be available in the US only after its Schedule IV designation is effective on June 7, 2013.

Stock Information

Ticker:

ARNA

Exchange:

NASDAQ

Price:

8.30

Change:

+ 0.24

Open:

8.04

Previous Close: